COVID-19 - March 1, 2021
Pfizer and BioNTech to evaluate COVID-19 booster and new vaccine variants
Pfizer and BioNTech have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. The study will draw upon participants from the Phase 1 study in […]
COVID-19 - February 23, 2021
The SciLifeLab program on COVID-19 vaccine effects is launched
In December 2020, SciLifeLab and the Knut and Alice Wallenberg Foundation (KAW), announced a call for a national program studying the effects of COVID-19 vaccines. 24 proposals were submitted and now, the program is launched, with 10 projects approved for funding, according to a press release from SciLifeLab. “In both the situation we are in […]
COVID-19 - February 22, 2021
Capitainer’s system employed in COVID-19 study in the US
The company’s qDBS dried blood spot system for home sample collection is being used in a nation-wide randomized clinical trial on the role of Vitamin D in COVID-19 run by Harvard Medical School. Participants in the study, who are recruited throughout the U.S., aged >18 years, and recently diagnosed with COVID-19, are mailed the qDBS […]
COVID-19 - February 17, 2021
Investigating airborne transmission of COVID-19 using a robot
A joint project by VTT, the Tampere University and THL has studied the mechanisms of the droplet and aerosol transmission of COVID-19 and the methods for reducing the risk of transmission. The droplets of a cough or sneeze dry quickly, but the remaining small particles may remain in the air for hours. Small aerosols are […]
COVID-19 - February 17, 2021
Johnson & Johnson submits European cMAA
Johnson & Johnson has announced that Janssen-Cilag International has submitted a conditional Marketing Authorization Application (cMAA) to the European Medicines Agency (EMA) seeking authorization for its investigational single-dose Janssen COVID-19 vaccine candidate. The submission is based on efficacy and safety data from the Phase 3 ENSEMBLE clinical trial. Ready to begin distributing in Q2 2021 […]
COVID-19 - February 16, 2021
A majority retained protective antibodies 9 months after infection, shows new study
As many as 96 percent of those infected with COVID-19 retain protective antibodies for at least nine months after confirmed infection. This is shown by a study from Danderyd Hospital and Karolinska Institutet using antibody tests developed by researchers at KTH and the SciLifeLab Autoimmunity Profiling facility, among them, Peter Nilsson (SciLifeLab/KTH). The COMMUNITY study […]
